Trial · NCT00255346
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
NCT00255346, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2019-05-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dasatinib as Therapy for Myeloproliferative Disorders (MPDs). Trials, record NCT00255346. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00255346
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
- NCT number
- NCT00255346
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 68 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis, Hypereosinophilic Syndrome, Polycythemia Vera, Mastocytosis, Leukemia, Myelomonocytic, Chronic
- Interventions
- Dasatinib (BMS-354825)
- First posted
- 2005-11-18
- Last updated
- 2025-12-30
- Results first posted
- 2019-05-06
- Limitations and caveats
The outcome measures were collected and reported by participant diagnosis group. The Other Adverse Events and Serious Adverse Events were collected and recorded as a group for all participants registered on the study.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participant Response Rate | Baseline to completion of 4 week cycle or until disease progression | Response Rate is complete response plus partial response (CR+PR) for each disease category. Response Evaluation Criteria are as follows: Systemic Mastocytosis (SM): CR is the improvement of C-Findings, Tryptase \<20, and no organomegaly. PR is the improvement of C-Findings. Acute Myeloid Leukemia (AML)/MDS and CMML: CR is bone marrow blasts \</= 5%, absolute neutrophil count (ANC) \>/= 1000 and platelets \>/= 100. PR is bone marrow blasts 6-25% but decreased by \> 50% and absolute neutrophil count, absolute neutrophil count (ANC) \>/= 1000 and platelets \>/= 100. Primary Myelofibrosis (PMF): CR is bone marrow blasts \</= 5%, absolute neutrophil count (ANC) \>/= 1000 and platelets \>/= 100. CR is PR plus one or more of the following: ANC \>/= 1000, decreased platelets by 50%, hemoglobin increase of 2g/dl or reduction splenomegaly and/or hepatomegaly by 50%. HES/CEL: CR is disappearance of eosinophilia \</= 10%, PR is reduction of eosinophilia by \>/= 50% |
| Secondary | Duration of Response (Survival) | Baseline, once a week for a month, thereafter monthly, up to 10 years | Response date to loss of response or last follow up. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Participant Response Rate | Baseline to completion of 4 week cycle or until disease progression | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Duration of Response (Survival) | Baseline, once a week for a month, thereafter monthly, up to 10 years | The number of participants analyzed for duration of response reflects the number of participants with a response for each arm. | Months | MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Participant Response Rate | Acute Myeloid Leukemia (AML) | 1 | Participants | ||
| Participant Response Rate | MDS/CMML | 0 | Participants | ||
| Participant Response Rate | HES/CEL | 1 | Participants | ||
| Participant Response Rate | Primary Myelofibrosis (PMF) | 0 | Participants | ||
| Participant Response Rate | Systemic Mastocytosis (SM) | 2 | Participants | ||
| Duration of Response (Survival) | Acute Myeloid Leukemia (AML) | NA | Months | ||
| Duration of Response (Survival) | HES/CEL | NA | Months | ||
| Duration of Response (Survival) | Systemic Mastocytosis (SM) | 13 | Full Range 8 to 18 | Months |
Source ClinicalTrials.gov
Participant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Acute Myeloid Leukemia (AML) | 10 | |
| Overall Study | STARTED | MDS/CMML | 6 | |
| Overall Study | STARTED | HES/CEL | 8 | |
| Overall Study | STARTED | Primary Myelofibrosis (PMF) | 11 | |
| Overall Study | STARTED | Systemic Mastocytosis (SM) | 33 | |
| Overall Study | COMPLETED | Acute Myeloid Leukemia (AML) | 9 | |
| Overall Study | COMPLETED | MDS/CMML | 6 | |
| Overall Study | COMPLETED | HES/CEL | 8 | |
| Overall Study | COMPLETED | Primary Myelofibrosis (PMF) | 11 | |
| Overall Study | COMPLETED | Systemic Mastocytosis (SM) | 33 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events14
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhea | Gastrointestinal disorders | Dasatinib All Patient Groups | 5 | 68 | 5 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Dasatinib All Patient Groups | 18 | 68 | 18 |
| other | Edema | Blood and lymphatic system disorders | Dasatinib All Patient Groups | 5 | 68 | 5 |
| other | Fatigue | General disorders | Dasatinib All Patient Groups | 8 | 68 | 8 |
| other | Headache | General disorders | Dasatinib All Patient Groups | 12 | 68 | 12 |
| other | Nausea/Vomiting | Gastrointestinal disorders | Dasatinib All Patient Groups | 21 | 68 | 21 |
| other | Pain | General disorders | Dasatinib All Patient Groups | 7 | 68 | 7 |
| other | Platelets/Hemoglobin | Blood and lymphatic system disorders | Dasatinib All Patient Groups | 6 | 68 | 6 |
| other | Pleural Effusion | Respiratory, thoracic and mediastinal disorders | Dasatinib All Patient Groups | 14 | 68 | 14 |
| other | Rash | Skin and subcutaneous tissue disorders | Dasatinib All Patient Groups | 4 | 68 | 4 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dasatinib All Patient Groups | 2 | 68 |
| Total, other adverse events | Dasatinib All Patient Groups | 67 | 68 |
| Total, serious adverse events | Dasatinib All Patient Groups | 2 | 68 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00255346
GET https://conductscience.org/api/trials/v1/NCT00255346/registered